Cheng Yusheng, Gong Yihang, Chen Xiuxing, Zhang Qi, Zhang Xijian, He Yizhan, Pan Lijie, Ni Beibei, Yang Fan, Xu Yan, Zhou Lei, Yang Yang, Chen Wenjie
Department of Hepatic Surgery and Liver Transplantation Center & Guangdong Provincial Key Laboratory of Liver Disease Research, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, 510630, China.
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Medical Oncology. Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China.
Biomaterials. 2022 May;284:121506. doi: 10.1016/j.biomaterials.2022.121506. Epub 2022 Apr 1.
Post-resection recurrence remains an intractable problem in hepatocellular carcinoma (HCC) management. Natural killer (NK) cell infusion is considered as a promising cancer therapy, but acidic tumor microenvironment (TME) and neutrophil extracellular traps (NETs) greatly counteract its efficacy. Recently, polymer hydrogels have aroused much interest in tumor combination therapy, since they load and controllably release therapeutic agents with high bioavailability and low systemic toxicity. Therefore, a biocompatible hydrogel with tumor acidity neutralizer and NETs lyase may show promise for enhancing NK infusion to prevent post-resection HCC recurrence. Herein, a dual pH-responsive hydrogel with tumor acidity neutralizer (mesoporous bioactive glass nanoparticles) and NETs lyase (Deoxyribonuclease I, DNase I) is developed and used in combination with NK cell infusion for preventing post-resection HCC recurrence. The hydrogel can be injected to surgical margin and form an adhesive gel with a rapid hemostasis. Besides, it neutralizes tumor acidity to reduce tumor infiltration of immunosuppressive cells, and releases DNase I in a pH-responsive manner to degrade NETs. Moreover, this combination therapy significantly enhances NK cell infusion to combat post-surgical HCC recurrence without systemic toxicity. This study provides proof of concept that combination of NK cell adoptive therapy and hydrogel-based delivery system can successfully prevent post-resection HCC recurrence.
肝切除术后复发仍然是肝细胞癌(HCC)治疗中一个棘手的问题。自然杀伤(NK)细胞输注被认为是一种有前景的癌症治疗方法,但酸性肿瘤微环境(TME)和中性粒细胞胞外陷阱(NETs)极大地抵消了其疗效。近年来,聚合物水凝胶在肿瘤联合治疗中引起了广泛关注,因为它们能够负载并可控地释放治疗药物,具有高生物利用度和低全身毒性。因此,一种具有肿瘤酸度中和剂和NETs裂解酶的生物相容性水凝胶可能有望增强NK细胞输注,以预防肝切除术后HCC复发。在此,我们开发了一种具有肿瘤酸度中和剂(介孔生物活性玻璃纳米颗粒)和NETs裂解酶(脱氧核糖核酸酶I,DNase I)的双pH响应水凝胶,并将其与NK细胞输注联合使用,以预防肝切除术后HCC复发。该水凝胶可注射到手术切缘并形成具有快速止血作用的粘附凝胶。此外,它能中和肿瘤酸度,减少免疫抑制细胞的肿瘤浸润,并以pH响应方式释放DNase I以降解NETs。而且,这种联合治疗显著增强了NK细胞输注,以对抗肝切除术后HCC复发,且无全身毒性。本研究提供了概念验证,即NK细胞过继性治疗与基于水凝胶的递送系统相结合能够成功预防肝切除术后HCC复发。